Evaluation of a proteomic signature coupled with the kidney failure risk equation in predicting end stage kidney disease in a chronic kidney disease cohort.

Actin cytoskeleton pathway Biomarkers Chronic kidney disease (CKD) End-stage renal disease (ESRD) Kidney Failure Risk Equation (KFRE) Proteomics RHO GTPasses SWATH-MS Tight junction

Journal

Clinical proteomics
ISSN: 1542-6416
Titre abrégé: Clin Proteomics
Pays: England
ID NLM: 101184586

Informations de publication

Date de publication:
18 May 2024
Historique:
received: 16 02 2024
accepted: 25 04 2024
medline: 19 5 2024
pubmed: 19 5 2024
entrez: 18 5 2024
Statut: epublish

Résumé

The early identification of patients at high-risk for end-stage renal disease (ESRD) is essential for providing optimal care and implementing targeted prevention strategies. While the Kidney Failure Risk Equation (KFRE) offers a more accurate prediction of ESRD risk compared to static eGFR-based thresholds, it does not provide insights into the patient-specific biological mechanisms that drive ESRD. This study focused on evaluating the effectiveness of KFRE in a UK-based advanced chronic kidney disease (CKD) cohort and investigating whether the integration of a proteomic signature could enhance 5-year ESRD prediction. Using the Salford Kidney Study biobank, a UK-based prospective cohort of over 3000 non-dialysis CKD patients, 433 patients met our inclusion criteria: a minimum of four eGFR measurements over a two-year period and a linear eGFR trajectory. Plasma samples were obtained and analysed for novel proteomic signals using SWATH-Mass-Spectrometry. The 4-variable UK-calibrated KFRE was calculated for each patient based on their baseline clinical characteristics. Boruta machine learning algorithm was used for the selection of proteins most contributing to differentiation between patient groups. Logistic regression was employed for estimation of ESRD prediction by (1) proteomic features; (2) KFRE; and (3) proteomic features alongside KFRE. SWATH maps with 943 quantified proteins were generated and investigated in tandem with available clinical data to identify potential progression biomarkers. We identified a set of proteins (SPTA1, MYL6 and C6) that, when used alongside the 4-variable UK-KFRE, improved the prediction of 5-year risk of ESRD (AUC = 0.75 vs AUC = 0.70). Functional enrichment analysis revealed Rho GTPases and regulation of the actin cytoskeleton pathways to be statistically significant, inferring their role in kidney function and the pathogenesis of renal disease. Proteins SPTA1, MYL6 and C6, when used alongside the 4-variable UK-KFRE achieve an improved performance when predicting a 5-year risk of ESRD. Specific pathways implicated in the pathogenesis of podocyte dysfunction were also identified, which could serve as potential therapeutic targets. The findings of our study carry implications for comprehending the involvement of the Rho family GTPases in the pathophysiology of kidney disease, advancing our understanding of the proteomic factors influencing susceptibility to renal damage.

Sections du résumé

BACKGROUND BACKGROUND
The early identification of patients at high-risk for end-stage renal disease (ESRD) is essential for providing optimal care and implementing targeted prevention strategies. While the Kidney Failure Risk Equation (KFRE) offers a more accurate prediction of ESRD risk compared to static eGFR-based thresholds, it does not provide insights into the patient-specific biological mechanisms that drive ESRD. This study focused on evaluating the effectiveness of KFRE in a UK-based advanced chronic kidney disease (CKD) cohort and investigating whether the integration of a proteomic signature could enhance 5-year ESRD prediction.
METHODS METHODS
Using the Salford Kidney Study biobank, a UK-based prospective cohort of over 3000 non-dialysis CKD patients, 433 patients met our inclusion criteria: a minimum of four eGFR measurements over a two-year period and a linear eGFR trajectory. Plasma samples were obtained and analysed for novel proteomic signals using SWATH-Mass-Spectrometry. The 4-variable UK-calibrated KFRE was calculated for each patient based on their baseline clinical characteristics. Boruta machine learning algorithm was used for the selection of proteins most contributing to differentiation between patient groups. Logistic regression was employed for estimation of ESRD prediction by (1) proteomic features; (2) KFRE; and (3) proteomic features alongside KFRE.
RESULTS RESULTS
SWATH maps with 943 quantified proteins were generated and investigated in tandem with available clinical data to identify potential progression biomarkers. We identified a set of proteins (SPTA1, MYL6 and C6) that, when used alongside the 4-variable UK-KFRE, improved the prediction of 5-year risk of ESRD (AUC = 0.75 vs AUC = 0.70). Functional enrichment analysis revealed Rho GTPases and regulation of the actin cytoskeleton pathways to be statistically significant, inferring their role in kidney function and the pathogenesis of renal disease.
CONCLUSIONS CONCLUSIONS
Proteins SPTA1, MYL6 and C6, when used alongside the 4-variable UK-KFRE achieve an improved performance when predicting a 5-year risk of ESRD. Specific pathways implicated in the pathogenesis of podocyte dysfunction were also identified, which could serve as potential therapeutic targets. The findings of our study carry implications for comprehending the involvement of the Rho family GTPases in the pathophysiology of kidney disease, advancing our understanding of the proteomic factors influencing susceptibility to renal damage.

Identifiants

pubmed: 38762513
doi: 10.1186/s12014-024-09486-5
pii: 10.1186/s12014-024-09486-5
doi:

Types de publication

Journal Article

Langues

eng

Pagination

34

Subventions

Organisme : Medical Research Council
ID : MR/R013942/1
Pays : United Kingdom
Organisme : Manchester Biomedical Research Centre
ID : NIHR203308

Informations de copyright

© 2024. The Author(s).

Références

Hounkpatin HO, Harris S, Fraser SDS, Day J, Mindell JS, Taal MW, et al. Prevalence of chronic kidney disease in adults in England: comparison of nationally representative cross-sectional surveys from 2003 to 2016. BMJ Open. 2020;10(8): e038423.
doi: 10.1136/bmjopen-2020-038423 pubmed: 32792448 pmcid: 7430464
de Vries EF, Rabelink TJ, van den Hout WB. modelling the cost-effectiveness of delaying end-stage renal disease. Nephron. 2016;133(2):89–97.
doi: 10.1159/000446548 pubmed: 27270045
Kerr M, Bray B, Medcalf J, O’Donoghue DJ, Matthews B. Estimating the financial cost of chronic kidney disease to the NHS in England. Nephrol Dial Transplant. 2012;27(Suppl 3):73–80.
doi: 10.1093/ndt/gfs269
Murtagh FE, Addington-Hall J, Higginson IJ. The prevalence of symptoms in end-stage renal disease: a systematic review. Adv Chronic Kidney Dis. 2007;14(1):82–99.
doi: 10.1053/j.ackd.2006.10.001 pubmed: 17200048
Ali I, Kalra PA. A validation study of the 4-variable and 8-variable kidney failure risk equation in transplant recipients in the United Kingdom. BMC Nephrol. 2021;22(1):57.
doi: 10.1186/s12882-021-02259-4 pubmed: 33563222 pmcid: 7874608
Akbari S, Knoll G, White CA, Kumar T, Fairhead T, Akbari A. Accuracy of kidney failure risk equation in transplant recipients. Kidney Int Rep. 2019;4(9):1334–7.
doi: 10.1016/j.ekir.2019.05.009 pubmed: 31517152 pmcid: 6732728
Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational assessment of accuracy of equations for predicting risk of kidney failure: a meta-analysis. JAMA. 2016;315(2):164–74.
doi: 10.1001/jama.2015.18202 pubmed: 26757465 pmcid: 4752167
Ramirez Medina CR, Ali I, Baricevic-Jones I, Odudu A, Saleem MA, Whetton AD, et al. Proteomic signature associated with chronic kidney disease (CKD) progression identified by data-independent acquisition mass spectrometry. Clin Proteomics. 2023;20(1):19.
doi: 10.1186/s12014-023-09405-0 pubmed: 37076799 pmcid: 10116780
Ali I, Ibrahim ST, Chinnadurai R, Green D, Taal M, Whetton TD, et al. A paradigm to discover biomarkers associated with chronic kidney disease progression. Biomark Insights. 2020;15:1177271920976146.
doi: 10.1177/1177271920976146 pubmed: 33311975 pmcid: 7716058
Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.
doi: 10.7326/0003-4819-150-9-200905050-00006 pubmed: 19414839 pmcid: 2763564
Sumida K NG, Grams ME, Sang Y, Ballew SH, Coresh J, et al. Conversion of urine protein–creatinine ratio or urine dipstick protein to urine albumin–creatinine ratio for use in chronic kidney disease screening and prognosis: Johns Hopkins University. 2015. https://ckdpcrisk.org/pcr2acr/ .
Ali I, Donne RL, Kalra PA. A validation study of the kidney failure risk equation in advanced chronic kidney disease according to disease aetiology with evaluation of discrimination, calibration and clinical utility. BMC Nephrol. 2021;22(1):194.
doi: 10.1186/s12882-021-02402-1 pubmed: 34030639 pmcid: 8147075
Major RW, Shepherd D, Medcalf JF, Xu G, Gray LJ, Brunskill NJ. The kidney failure risk equation for prediction of end stage renal disease in UK primary care: an external validation and clinical impact projection cohort study. PLoS Med. 2019;16(11): e1002955.
doi: 10.1371/journal.pmed.1002955 pubmed: 31693662 pmcid: 6834237
Geary B, Walker MJ, Snow JT, Lee DCH, Pernemalm M, Maleki-Dizaji S, et al. Identification of a biomarker panel for early detection of lung cancer patients. J Proteome Res. 2019;18(9):3369–82.
doi: 10.1021/acs.jproteome.9b00287 pubmed: 31408348
Ortea I, Ruiz-Sánchez I, Cañete R, Caballero-Villarraso J, Cañete MD. Identification of candidate serum biomarkers of childhood-onset growth hormone deficiency using SWATH-MS and feature selection. J Proteomics. 2018;175:105–13.
doi: 10.1016/j.jprot.2018.01.003 pubmed: 29317355
Salie MT, Yang J, Ramirez Medina CR, Zuhlke LJ, Chishala C, Ntsekhe M, et al. Data-independent acquisition mass spectrometry in severe rheumatic heart disease (RHD) identifies a proteomic signature showing ongoing inflammation and effectively classifying RHD cases. Clin Proteomics. 2022;19(1):7.
doi: 10.1186/s12014-022-09345-1 pubmed: 35317720 pmcid: 8939134
Acharjee A, Larkman J, Xu Y, Cardoso VR, Gkoutos GV. A random forest based biomarker discovery and power analysis framework for diagnostics research. BMC Med Genomics. 2020;13(1):178.
doi: 10.1186/s12920-020-00826-6 pubmed: 33228632 pmcid: 7685541
Kursa MB, Rudnicki WR. Feature selection with the boruta package. J Stat Softw. 2010;36(11):1–13.
doi: 10.18637/jss.v036.i11
Polo TCF, Miot HA. Use of ROC curves in clinical and experimental studies. J Vasc Bras. 2020;19: e20200186.
doi: 10.1590/1677-5449.200186 pubmed: 34211533 pmcid: 8218006
Aleshin AE, Schraufstatter IU, Stec B, Bankston LA, Liddington RC, DiScipio RG. Structure of complement C6 suggests a mechanism for initiation and unidirectional, sequential assembly of membrane attack complex (MAC). J Biol Chem. 2012;287(13):10210–22.
doi: 10.1074/jbc.M111.327809 pubmed: 22267737 pmcid: 3323040
Thurman JM. Complement in kidney disease: core curriculum 2015. Am J Kidney Dis. 2015;65(1):156–68.
doi: 10.1053/j.ajkd.2014.06.035 pubmed: 25441433
Berger SP, Roos A, Daha MR. Complement and the kidney: what the nephrologist needs to know in 2006? Nephrol Dial Transplant. 2005;20(12):2613–9.
doi: 10.1093/ndt/gfi166 pubmed: 16204271
Koopman JJE, van Essen MF, Rennke HG, de Vries APJ, van Kooten C. Deposition of the membrane attack complex in healthy and diseased human kidneys. Front Immunol. 2020;11: 599974.
doi: 10.3389/fimmu.2020.599974 pubmed: 33643288
Rauscher CK, Fajt ML, Bryk J, Petrov AA. Clinical implications of C6 complement component deficiency. Allergy Asthma Proc. 2020;41(5):386–8.
doi: 10.2500/aap.2020.41.200039 pubmed: 32867893
Grumach AS, Kirschfink M. Complement Deficiencies. In: Rezaei N, editor. Encyclopedia of infection and immunity. Oxford: Elsevier; 2022. p. 556–63.
doi: 10.1016/B978-0-12-818731-9.00198-1
Hsieh LT, Nastase MV, Zeng-Brouwers J, Iozzo RV, Schaefer L. Soluble biglycan as a biomarker of inflammatory renal diseases. Int J Biochem Cell Biol. 2014;54:223–35.
doi: 10.1016/j.biocel.2014.07.020 pubmed: 25091702
Singh S, Wu T, Xie C, Vanarsa K, Han J, Mahajan T, et al. Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis. Arthritis Res Ther. 2012;14(4):R164.
doi: 10.1186/ar3912 pubmed: 22788914 pmcid: 3580557
Jeruschke S, Büscher AK, Oh J, Saleem MA, Hoyer PF, Weber S, et al. Protective effects of the mTOR inhibitor everolimus on cytoskeletal injury in human podocytes are mediated by RhoA signaling. PLoS ONE. 2013;8(2): e55980.
doi: 10.1371/journal.pone.0055980 pubmed: 23418489 pmcid: 3572151
Schiffer M, Teng B, Gu C, Shchedrina VA, Kasaikina M, Pham VA, et al. Pharmacological targeting of actin-dependent dynamin oligomerization ameliorates chronic kidney disease in diverse animal models. Nat Med. 2015;21(6):601–9.
doi: 10.1038/nm.3843 pubmed: 25962121 pmcid: 4458177
Reiser J, Sever S. Podocyte biology and pathogenesis of kidney disease. Annu Rev Med. 2013;64:357–66.
doi: 10.1146/annurev-med-050311-163340 pubmed: 23190150
Ahmadian E, Eftekhari A, Atakishizada S, Valiyeva M, Ardalan M, Khalilov R, et al. Podocytopathy: the role of actin cytoskeleton. Biomed Pharmacother. 2022;156: 113920.
doi: 10.1016/j.biopha.2022.113920 pubmed: 36411613
Solanki AK, Srivastava P, Rahman B, Lipschutz JH, Nihalani D, Arif E. The use of high-throughput transcriptomics to identify pathways with therapeutic significance in podocytes. Int J Mol Sci. 2019;21(1):274.
doi: 10.3390/ijms21010274 pubmed: 31906131 pmcid: 6981397
Mukherjee K, Gu C, Collins A, Mettlen M, Samelko B, Altintas MM, et al. Simultaneous stabilization of actin cytoskeleton in multiple nephron-specific cells protects the kidney from diverse injury. Nat Commun. 2022;13(1):2422.
doi: 10.1038/s41467-022-30101-4 pubmed: 35504916 pmcid: 9065033
Steichen C, Hervé C, Hauet T, Bourmeyster N. Rho GTPases in kidney physiology and diseases. Small GTPases. 2022;13(1):141–61.
doi: 10.1080/21541248.2021.1932402 pubmed: 34138686
Babelova A, Jansen F, Sander K, Löhn M, Schäfer L, Fork C, et al. Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease. PLoS ONE. 2013;8(11): e80328.
doi: 10.1371/journal.pone.0080328 pubmed: 24244677 pmcid: 3820652
Hou J. The kidney tight junction (review). Int J Mol Med. 2014;34(6):1451–7.
doi: 10.3892/ijmm.2014.1955 pubmed: 25319473 pmcid: 4214347
Lee DB, Huang E, Ward HJ. Tight junction biology and kidney dysfunction. Am J Physiol Renal Physiol. 2006;290(1):F20-34.
doi: 10.1152/ajprenal.00052.2005 pubmed: 16339962
Ali I, Chinnadurai R, Ibrahim ST, Kalra PA. Adverse outcomes associated with rapid linear and non-linear patterns of chronic kidney disease progression. BMC Nephrol. 2021;22(1):82.
doi: 10.1186/s12882-021-02282-5 pubmed: 33676423 pmcid: 7937251

Auteurs

Carlos Raúl Ramírez Medina (CR)

Stoller Biomarker Discovery Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK. carlos.ramirezmedina@manchester.ac.uk.

Ibrahim Ali (I)

Salford Royal Hospital, Northern Care Alliance Foundation NHS Trust, Salford, UK.
Division of Cardiovascular Sciences, The University of Manchester, Manchester, UK.

Ivona Baricevic-Jones (I)

Stoller Biomarker Discovery Centre, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK.
Salford Royal Hospital, Northern Care Alliance Foundation NHS Trust, Salford, UK.

Moin A Saleem (MA)

Bristol Renal and Children's Renal Unit, Bristol Medical School, University of Bristol, Bristol, UK.

Anthony D Whetton (AD)

Veterinary Health Innovation Engine (vHive), Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.

Philip A Kalra (PA)

Salford Royal Hospital, Northern Care Alliance Foundation NHS Trust, Salford, UK.

Nophar Geifman (N)

School of Health Sciences, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK.

Classifications MeSH